CRISPR Therapeutics has revealed promising but early data from its first clinical study of a gene editing therapy to lower ...

Vinay Prasad named to replace Peter Marks as head of FDA's Center for Biologics Evaluation and Research; discussion planned ...

Novo Nordisk cuts 2025 revenue guidance due to higher than expected impact of US compound pharmacies producing semaglutide.

How did biopharma stocks react to Vinay Prasad’s appointment as director of one of the FDA's top jobs? Not well. Prasad, a ...

Marea Therapeutics said on Wednesday that its lipid-lowering antibody cut both remnant cholesterol levels and remnant ...

Sarepta's stock falls 48% after FDA critic Vinay Prasad's appointment and poor Elevidys sales. Company cuts revenue forecast ...

Attorneys general from 19 states and Washington, DC have filed a lawsuit against the federal government alleging that its ...

House and Senate lawmakers from both parties are working with the Trump administration on proposals that would use drug ...

The FDA on Tuesday said it is planning on doing more surprise inspections of foreign factories, a day after Trump signed an ...

Plus, news about Atara Bio­ther­a­peu­tics, Im­mutep, blue­bird bio, OSE Im­munother­a­peu­tics, Mer­sana Ther­a­peu­tics, ...

Vertex said it's gathering momentum with its new product launches, building out new franchises with its sickle cell therapy ...

Several members of an FDA advisory committee warned on Monday that new data from studies on long-term use of opioids might ...